11 Mar 2021 Clinical Research Forum, Nanchang, China
01 About us
The year 2020 marks the milestone year of the Chinese Acute Pancreatitis Trials Group (CAPCTG), and also the year of the achievements of the Chinese Critical Care Nutrition Trials Group (CCCNTG). In 2021, we will set sail and forge ahead together. On March 6, 2021, we met in Nanchang and started the first stop of our clinical research forum to share our clinical research progress and other contents.
02 Clinical Experts
Professor Lu Nonghua of the Gastroenterology Department of the First Affiliated Hospital of Nanchang University and Professor Li Weiqin of the ICU Department of the Eastern Theater Command General Hospital delivered the opening speech. The two sides affirmed the importance of teamwork. Professor Li would like to express his deep gratitude to colleagues in the field of digestion and critical diseases in Jiangxi for their support to the team work. And they hope to continue to carry out academic exchanges and cooperation in the future so as to make greater progress. The two professors extend a warm welcome to all the distinguished guests and colleagues.
03 Project Introduction
Professor Tong Zhihui and Professor Ke Lu from the General Hospital of the Eastern Theater Command introduced the multi-center research projects and progress of CAPCTG and CCCNTG.
The current guidelines recommend that critically ill patients be given adequate protein, but the level of evidence is low. We intend to investigate the effect of early intravenous amino acid supplementation on the mortality of patients with normal renal function in a multicenter, randomized controlled trial. It is expected that 30 ICU,1838 patients who meet the enrollment criteria will be recruited in China and randomly divided into amino acid therapy group and routine treatment group. Patients in the amino acid treatment group received additional infusion of standard compound amino acid injection (18AA-VII) immediately on the second natural day after randomization to achieve the target protein dose of about 2.0g/kg/d. Patients in the routine treatment group were given amino acids according to the local clinical practice of ICU. By comparing the clinical prognosis of the two groups of patients, to provide a more reliable clinical evidence-based basis for the current low level of evidence guidelines and clinical practice.
In view of the lack of data reflecting the “real world” status of protein supplementation in China, we plan to conduct a multicenter, prospective and observational cohort study to describe the current situation of protein supplementation in China. And to explore the impact of the number and source of protein supplementation on the clinical outcome of critically ill patients. It is planned to be conducted in the ICU of 30-50 hospitals in China, and each participating center is enrolled in the group continuously for one month. We expect to collect the data of 1500-2000 patients within 2 years to explore the effects of protein supplementation and pathway of protein supplementation on organ dysfunction within 7 days, organ support therapy, and clinical outcomes at 28 and 90 days after enrollment.
The perform study, which aims to explore the effect of early plasma exchange on organ function in patients with hyperlipidemic acute pancreatitis, is a multicenter registration study. This study was initiated by the Eastern Theater General Hospital and officially joined the group in December 2020. 39 sub-centers have been recruited so far, with a total of 45 cases. It is expected to collect data of 500 patients in one year. This study mainly included the patients with high lactic acid / low calcium / sirs/ organ dysfunction within 72 hours after onset, and the blood lipid level, lipid-lowering therapy and organ function within 14 days were recorded to explore the effect of lipid-lowering therapy including plasma exchange on the outcome indexes such as days without organ failure within 14 days.
This special forum on clinical research is of great significance! At the beginning of the first stop of the 2021 Clinical Research Forum, we shared our research progress, shared our gains and losses in 2020, and had a bright vision of a new journey in 2021. I believe that with our efforts CAPCTG and CCCNTG will achieve better results in 2021. Let us sail in 2021!